Immunocore Holdings plc IMCR
Immunocore Holdings plc (Nasdaq: IMCR) is an oncology drug developer. Its lead program, KIMMTRAK (tebentafusp), is in Phase 3 for unresectable or metastatic uveal melanoma. Its next catalyst on record is tebentafusp (TEBE-AM): Phase 3 topline data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tebentafusp (TEBE-AM) — Phase 3 topline data (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KIMMTRAK (tebentafusp) | metastatic uveal melanoma | biologic-other | Approved |
| tebentafusp (TEBE-AM) | previously treated advanced cutaneous melanoma | biologic-other | Phase 3 |
| tebentafusp (ATOM) | adjuvant uveal melanoma | biologic-other | Phase 3 |
| brenetafusp (PRISM-MEL-301) | first-line advanced cutaneous melanoma | biologic-other | Phase 3 |
| brenetafusp (PRAME-101) | multiple PRAME-positive tumor types | biologic-other | Phase 1 |
| IMC-R117C (PIWIL-1) | advanced solid tumors incl. colorectal cancer | biologic-other | Phase 1 |
| IMC-P115C (PRAME-HLE-A02) | PRAME-expressing tumors | biologic-other | Phase 1 |
| IMC-M113V | HIV functional cure | biologic-other | Phase 1 |
| IMC-S118AI | type 1 diabetes | biologic-other | Pre-clinical |
| IMC-U120AI | autoimmune disease | biologic-other | Pre-clinical |
Recent results and decisions
- Sep 14, 2026completed enrollment TEBE-AM Phase 3 reached its target enrollment of 540 patients; primary endpoint is overall survival.
today announced the achievement of target patient enrollment (540 patients) in the TEBE-AM clinical trial (NCT05549297).
Filing - Aug 6, 2026positive ASCO 2026 Phase 1/2 data: brenetafusp 160 mcg monotherapy ORR 17% and DCR 67% vs ORR 6% and DCR 56% at 40 mcg; median OS 14.3 months; supports Phase 3 dose.
The Phase 1/2 data, presented at the 2026 ASCO meeting, showed improved clinical activity of brenetafusp monotherapy, in patients with heavily-pretreated advanced melanoma, with an overall response rate (ORR) of 17% and a disease control rate (DCR) of 67%
Filing - May 6, 2026positive Five-year OS follow-up of the Phase 3 mUM trial (n=378) showed 16% vs 8% alive at 5 years (HR 0.67) and median OS 21.6 vs 16.9 months for KIMMTRAK vs investigator's choice.
In this study of 378 patients, KIMMTRAK doubled the likelihood of being alive at five years with an OS rate of 16% versus 8% in the control arm (HR 0.67), while demonstrating a median OS of 21.6 months compared to 16.9 months for investigator’s choice.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.